Roche's Ocrevus (ocrelizumab) is better at controlling disease activity in relapsing multiple sclerosis than German Merck's Rebif (interferon beta-1a), according to ...

whereas patients on Rebif deteriorated. The benefits were long lived, lasting at least three years. Even more striking, perhaps, are the magnetic resonance imaging scans that suggest the drug may ...

Five forms of beta interferon (Avonex, Betaseron, Extavia, Plegridy, and Rebif) are currently approved by the Food and Drug Administration for treatment of relapsing-remitting MS. Beta interferon is ...